SELVAS AI to Receive CES 2018 Innovation Award for Disease Prediction Solution Using Artificial Intelligence


(MENAFN- Investors Ideas) SEOUL, South Korea - November 10, 2017 (Investorideas.com Newswire) SELVAS AI (KOSDAQ:108860), an artificial intelligence company, will receive CES 2018 Innovation Award for its AI disease prediction solution "Selvy Checkup" at the CES (Consumer Electronics Show) 2018, one of the largest global consumer electronics tradeshows in Las Vegas, Nevada, USA in January next year.

Winners of CES Innovation Awards are chosen by Consumer Technology Association (CTA) and Industrial Designers Society of America (IDSA) which evaluate products in 28 categories in terms of technology, innovativeness and design.

Selvy Checkup is a medical service that predicts the probabilities of incidence within two or three years for six most common cancers including lung and liver cancers and major adult diseases including cardio-cerebrovascular disease and diabetes. It is provided as part of health checkup.

The service was developed through joint research by big data analysts and clinical research physicians in various fields. It is considered one of the best medical AI solutions. The CES 2018 award is meaningful to medical and IT industries in that it is a worldwide recognition of the superb technology and excellent innovativeness of the service jointly researched by large hospitals and SELVAS AI.

The incidence of adult diseases is rising due to rapid population aging and unhealthy habits of the modern life. Adult diseases are one of the leading causes of death in the world, but they are preventable and curable at an early stage if they are predicted and managed. Selvy Checkup has been selected as a CES 2018 Innovation Award winner in the category of "Tech for a Better World" in recognition of its intelligent disease forecasting system which contributes to the efficient control of adult diseases and the promotion of people's health.

SELVAS AI will exhibit its products at a booth (Hall A-D Sands #43849) in the CES 2018 from Jan. 9-12 in Las Vegas, USA.

SELVAS AI

SELVAS AI is an artificial intelligence company that does AI-related businesses in diverse fields including medical care, finance, automobiles and assistive technology on the basis of machine learning techniques. It possesses core AI technologies such as voice, handwriting and image intelligences and AI convergence technology which combines those core technologies. All the technologies of SELVAS AI are based on machine learning platform.

Contacts

Selvas Group Communication Center
Kate Kim, +82-2-6190-7676

PR Agency Ketchum
Jiyoung Moon, +82-2-559-9611

Haeri Na, +82-2-559-9627


TechSectorStocks.com - investing ideas in tech stocks - mobile payments, social media, AI and Robotics, Drone Stocks, GPS, Internet of Things (IoT)

Like Tech Stocks? View our


More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: . Global investors must adhere to regulations of each country.




MENAFN1011201701420000ID1096069747


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.